Sienna Biopharm (NASDAQ:SNNA) General Counsel Timothy K. Andrews acquired 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The shares were bought at an average price of $15.00 per share, with a total value of $225,000.00. Following the completion of the transaction, the general counsel now directly owns 51,737 shares in the company, valued at $776,055. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Shares of Sienna Biopharm (NASDAQ SNNA) traded up 1.73% on Friday, hitting $19.38. The company had a trading volume of 76,768 shares. Sienna Biopharm has a 12 month low of $18.50 and a 12 month high of $21.20.
WARNING: This piece was originally reported by Rincon Hill News and is owned by of Rincon Hill News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://rinconhillneighbors.org/2017/08/19/sienna-biopharmaceuticals-inc-snna-general-counsel-buys-225000-00-in-stock-updated-updated.html.
Sienna Biopharm Company Profile
Sienna Biopharmaceuticals, Inc is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125.
Receive News & Ratings for Sienna Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharm and related companies with our FREE daily email newsletter.